Receptor binding and mitogenic effects of insulin and insulinlike growth factors I and II for human myeloid leukemic cells.

Insulin and insulinlike growth factors I and II (IGF-I and IGF-II) influence mesodermal cell proliferation and differentiation. As multiple growth factors are involved in hemopoietic cell proliferation and differentiation, we assessed the receptor binding and mitogenic effects of these peptides on a panel of mesodermally derived human myeloid leukemic cell lines. The promyelocytic cell line HL60 had the highest level of specific binding for these 125I-labeled ligands, with lower binding to the less differentiated myeloblast cell line KG1 and undifferentiated blast variants of these cell lines (HL60blast, KG1a). Insulin binding affinity and receptor numbers were reduced significantly by chemically induced granulocytic differentiation of HL60 cells and was unchanged following induced monocytic differentiation. No substantial alteration in IGF-I or -II binding occurred with induced HL60 cell differentiation. Insulin and IGF-I demonstrated cross competition for receptor binding and down-regulated their homologous receptors without detectable cross modulation of the heterologous receptors on HL60 cells. IGF-I and insulin increased HL60 cell proliferation, as assessed by 3H-thymidine uptake, IGF-I greater than insulin. IGF-I binding and mitogenic effects were blocked by the monoclonal anti-IGF-I receptor antibody IR3, indicating that IGF-I-induced proliferative effects were mediated via its homologous receptor. In contrast, insulin binding and mitogenesis displayed blocking by both anti-IGI-I and anti-insulin receptor antibodies, indicating mediation of its activity through both receptors. These data demonstrate specific binding and mitogenic interactions between insulin, IGFs, and hemopoietic cells which are associated with their state of differentiation.

Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In.

A normal plasma lipoprotein, termed LDL-In, has been shown to be a potent inhibitor of mitogen-driven human lymphocyte proliferation in vitro and of primary antibody responses in the mouse. To determine whether the immunoregulatory activity of LDL-In resided with the protein rather than the lipid constituents of LDL-In, one of the apoproteins of LDL-In, apoprotein E, was isolated from plasma and was analyzed for its inhibitory activity. Apoprotein E, isolated after delipidization of lipoproteins with either methyl ethyl ketone or ethanol and ethyl ether, was immunosuppressive. Furthermore, the characteristics of inhibition of cellular [3H]thymidine uptake by isolated apoprotein E were identical to those characteristics obtained with suppression by LDL-In. Inhibition by apoprotein E and LDL-In required preincubation of the cells with either apoprotein or lipoprotein for 24 hr before exposure of the cells to mitogen for maximal expression of suppressive activity, and this inhibition could not be reversed by removal of non-cell-associated inhibitor before stimulation. Neither apoprotein E or LDL-In was inhibitory when they were added to the cells after mitogen stimulation. The only difference noted between suppression by apoprotein E and LDL-In was that of dose. Compared with quantitative estimates of the apoprotein E content of LDL-In, significantly more isolated apoprotein E was required than lipoprotein-associated E for comparable levels of suppression. The potency of apoprotein E could be increased by adding it to cells in the presence of dimyristoylphosphatidylcholine/cholesterol vesicles. The data suggesting that phospholipid increased the specific activity of apoprotein E by altering its molecular dispersion was obtained from analyses of the interaction of apo E with cells, as well as the plastic culture vessels. The results suggested that the molecular dispersion and perhaps organization of isolated apoprotein E in an aqueous system is critical to its interaction with lymphocytes and subsequently its biological activity.